Alpha-1 Antitrypsin DeficiencyGeneticsRare diseaseProcedure
What this study is
The Alpha-1 Coded Testing (ACT) Study was established to study genetic testing and outcomes of individuals at risk for alpha-1 antitrypsin deficiency.
What's being tested
- Alpha-1 Antitrypsin Genotype
Intervention · PROCEDURE
Home fingerstick testing for alpha-1 antitrypsin genotype
Study details
- Sponsor
- University of Florida
- Conditions
- Alpha-1 Antitrypsin Deficiency
- Enrolling
- 50,000 people
- Starts
- 2001-01
- Est. completion
- 2050-01
- Record
- View on ClinicalTrials.gov ↗
Who can join
Sex ALLHealthy volunteers AcceptedYou may qualify if
- Individuals of any age at risk for alpha-1 antitrypsin deficiency on the basis of symptoms or family genetic risk.
You can't join if
- Any person who has already had genotype and AAT level testing completed and has a qualified result.
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
1
Study locations (1)
1 openUniversity of Florida
Gainesville, Florida, United States
- Michelle Owens, RN, BSN · Contact352-273-6339Sandra.Owens@medicine.ufl.edu
- Allison Faunce, B.A. · Contact352-273-8666Allison.Faunce@medicine.ufl.edu
- Karina Serban, M.D. · Principal investigator
Recruiting
Study team
Sponsor
University of Florida
Study ID IRB201903430
Principal investigator
Karina Serban, M.D.
University of Florida
Have questions? The contacts above can answer them before you apply.
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.